Reading MRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRKR free→Reading MRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRKR free→QuarterlyIQ Insights · MRKR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Appointment of New Director. On October 31, 2025, the board of directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Ms. Kathryn Penkus Corzo to the Company’s Board, effective November 1, 2025. Kathryn Penkus Corzo, RPh, MBA, served on the Board of Directors of Matinas Biopharma Holdings, Inc. between September 2021…
Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), the former independent registered public accounting firm of Marker Therapeutics, Inc. (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through August 6, 2025. On August 6, 2025, Marcum resigned as the Company’s independent registered public…
Entry into a Material Definitive Agreement. On June 16, 2025, Marker Therapeutics, Inc. (the “Company”) entered into a Statement of Work (the “SOW”) with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for the manufacturing of MT-601, the Company’s lead Multi-Antigen Recognizing (MAR)-T cell therapy. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of…
of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers. Chief Executive Officer Stock Option Award . On February 12, 2025, the Compensation Committee and Board of Directors of Marker Therapeutics, Inc. (the “Company”) approved a discretionary award of 50,000 stock options (the “CEO Options”) to Dr. Juan Vera, the Company’s Chief Executive Officer under t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers. (e) Compensatory Arrangements of Certain Officers. Chief Executive Officer Stock Option Award . On February 12, 2024, the Compensation Committee and Board of Directors of Marker Therapeutics, Inc. (the “Company”) approved a discretionary award of 50,000 stock options (the “CEO Options”) to Dr. Juan Vera, the Company’s Chief Executive Officer under t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Compensatory Arrangements of Certain Officers. (b) Resignation of Director. On January 24, 2025, Mr. John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc. (the “Company”). Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the R…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.